Please note most of these publications were published by our predecessor company CellPoint, LLC.

Cell>Point to present at 52nd American Society of Hematology Annual Meeting December 4-7, 2010.

CENTENNIAL, Colo., December 1, 2010 – Dr. Lan V. Pham, Department of Hematophathology, The University of Texas M.D. Anderson Cancer Center, will be presenting the following paper titled “Metabolic Targeted Therapy for Aggressive B-cell Lymphomas: Evaluating Glucose Metabolism and the Potential of 187Rhenium-Ethylenedicysteine – N- AcetylGlucosamine (187Re-EC-G) for Therapy” at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida. 187Re-ECG utilizes Cell>Point’s intra-nuclear targeting technology EC-G.  The company successfully targeted lymphoma with EC-G in its Phase 1 99mTc-EC-G imaging trial conducted several years ago.  By substituting 99mTc with 187Re, the targeted diagnostic imaging agent is converted into a target specific therapeutic agent.  Key findings of the presentation show that 187Re-EC-G enters the nucleus and impacts the DNA which leads to lymphoma cell apoptosis.  An additional finding suggests that 187Re-Ec-G is an excellent potential candidate for targeted therapy in aggressive r/r lymphomas.